Abstract:The monkeypox virus (MPOX) is an uncommon zoonotic illness brought on by an orthopoxvirus (OPXV). MPOX can occur with symptoms similar to smallpox. Since April 25, 2023, 110 nations have reported 87,113 confirmed cases and 111 fatalities. Moreover, the outspread prevalence of MPOX in Africa and a current outbreak of MPOX in the U.S. have made it clear that naturally occurring zoonotic OPXV infections remain a public health concern. Existing vaccines, though they provide cross-protection to MPOX, are not specific for the causative virus, and their effectiveness in the light of the current multi-country outbreak is still to be verified. Furthermore, as a sequel of the eradication and cessation of smallpox vaccination for four decades, MPOX found a possibility to re-emerge, but with distinct characteristics. The World Health Organization (WHO) suggested that nations use affordable MPOX vaccines within a framework of coordinated clinical effectiveness and safety evaluations. Vaccines administered in the smallpox control program and conferred immunity against MPOX. Currently, vaccines approved by WHO for use against MPOX are replicating (ACAM2000), low replicating (LC16m8), and non-replicating (MVA-BN). Although vaccines are accessible, investigations have demonstrated that smallpox vaccination is approximately 85% efficient in inhibiting MPOX. In addition, developing new vaccine methods against MPOX can help prevent this infection. To recognize the most efficient vaccine, it is essential to assess effects, including reactogenicity, safety, cytotoxicity effect, and vaccine-associated side effects, especially for high-risk and vulnerable people. Recently, several orthopoxvirus vaccines have been produced and are being evaluated. Hence, this review aims to provide an overview of the efforts dedicated to several types of vaccine candidates with different strategies for MPOX, including inactivated, live-attenuated, virus-like particles (VLPs), recombinant protein, nucleic acid, and nanoparticle-based vaccines, which are being developed and launched.

mRNA-based monkeypox virus vaccine prevents disease in non-human primates

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease

Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates

A Quadrivalent Mrna Immunization Elicits Potent Immune Responses Against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models

An overview on mRNA-based vaccines to prevent monkeypox infection

Monkeypox mRNA vaccine protects mice and macaques

Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus

Mpox mRNA-1769 Vaccine Inhibits Orthopoxvirus Replication at Intranasal, Intrarectal, and Cutaneous Sites of Inoculation

Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus

Old and new mpox vaccine

An MPXV Mrna-Lnp Vaccine Candidate Elicits Protective Immune Responses Against Monkeypox Virus

Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice

Progress and prospects on vaccine development against monkeypox infection

Advancements in monkeypox vaccines development: a critical review of emerging technologies

mRNA vaccines: A promising platform for safer, more effective next-generation Orthopoxvirus immunization

A Penta-Component Mpox Mrna Vaccine Induces Protective Immunity in Nonhuman Primates

An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge

Strategy of developing nucleic acid-based universal monkeypox vaccine candidates

Poxvirus vaccines: the evolution of an 18th-century vaccine to the 21st century

Prevention and Treatment of Monkeypox: A Systematic Review of Preclinical Studies

An mpox quadrivalent mRNA vaccine protects mice from lethal vaccinia virus challenge